Tevogen Bio Holdings Inc. (Nasdaq: TVGN) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company is a clinical-stage immunotherapy developer and has generated no product revenue. It completed its business combination with Semper Paratus on February 14, 2024; the transaction was accounted for as a reverse recapitalization, with Tevogen Bio treated as the accounting acquirer.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $20.8 million | $1.3 million |
| General and administrative expense | $8.7 million | $1.0 million |
| Total operating expenses / operating loss | $29.5 million | $2.3 million |
| Net income (loss) | $11.3 million | $(30.8) million |
| Cash used in operating activities | $2.2 million | $2.2 million |
| Cash at period end | $1.3 million | $5.7 million at March 31, 2023 |
The reported Q1 net income was not driven by sales or operating performance. It primarily reflected a $48.5 million noncash gain from the decrease in fair value of convertible notes before their conversion in the merger. Results also included $7.5 million of merger transaction costs and $26.3 million of stock-based compensation. Basic EPS was $0.08, while diluted EPS was a loss of $0.26, reflecting the treatment of the convertible-note fair-value gain in diluted EPS.
At March 31, 2024, total assets were $3.4 million and total liabilities were $9.2 million, with a stockholders’ deficit of $5.8 million. Current assets were $2.4 million versus current liabilities of $8.9 million. Accounts payable totaled $5.2 million. The company had an accumulated deficit of $88.4 million. No meaningful revenue-based margin measure is available.
Changes, financing and capital structure
- Operating expenses rose substantially year over year, largely because the merger triggered recognition of stock-based compensation tied to liquidity conditions. R&D and G&A included $19.0 million and $6.3 million, respectively, of this compensation.
- Convertible promissory notes were converted into common stock in connection with the merger; $46.6 million was recorded as a noncash conversion. At March 31, no convertible notes remained outstanding.
- The company assumed $1.651 million of non-interest-bearing notes payable to Polar. Repayment was due within five business days of the merger, and the company disclosed it was in default at March 31. The filing says the default provisions require the Sponsor—not the company—to transfer shares, subject to a cap; Polar waived the Sponsor’s transfer for the initial month of default.
- Q1 financing cash inflows were $2.4 million, including $2.0 million from Series A preferred stock, a $0.2 million Series A-1 deposit, and cash acquired in the merger. Series A carries a cumulative dividend initially set at 5% annually, increasing by 2% each year. Series B preferred stock was issued to the Sponsor in connection with assumed liabilities; the associated liabilities remained on the balance sheet because creditors had not legally released the company.
- Common shares issued and outstanding were 164.6 million at March 31; the cover page reports 166.1 million outstanding as of May 24. Potential dilution includes 17.25 million public warrants, 0.725 million private warrants, up to 24.5 million earnout shares, and equity awards.
Liquidity, outlook and risks
Management concluded that cash, together with financing received or expected, was insufficient to fund operations for 12 months from the financial statement issuance date and disclosed substantial doubt about the company’s ability to continue as a going concern. The statements are prepared on a going-concern basis and do not include adjustments that could result from an unfavorable outcome. Management is seeking additional funding; there is no assurance financing will be available on acceptable terms or at all.
After quarter-end, the company reported receiving $2.0 million toward Series A-1 preferred stock, with $4.8 million of the stated $6.0 million purchase price still expected. On May 10, it entered into a binding term sheet for an unsecured line of credit of up to $36.0 million, with monthly draws subject to terms, and a contingent option for the lender to purchase at least $14.0 million of common stock in a future private placement. A definitive agreement had not been signed, and the company cautioned that closing and proceeds were uncertain. The term sheet contemplates interest payable in shares and an equity purchase price set at a discount under specified conditions.
Management expects R&D and G&A expenses to increase as it advances clinical development, manufacturing capabilities and public-company operations. TVGN 489 completed a Phase 1 proof-of-concept trial in 2023; management plans a pivotal trial in COVID-19 patients with B-cell malignancies. Further clinical success, regulatory approval, commercialization, reimbursement and financing remain uncertain. The filing also identifies risks relating to clinical execution, manufacturing, competition, intellectual property, regulatory review and the company’s ability to continue as a going concern.
- Unusual items: The CEO received 19.35 million shares of restricted stock with a grant-date fair value of $87.3 million; vesting begins in 2031 and continues in four annual installments. The merger also triggered recognition of $25.2 million in compensation cost for performance-based RSUs.
- Controls: Management concluded disclosure controls were not effective at the reasonable-assurance level because of material weaknesses in internal control over financial reporting. No material change in internal control was reported during the quarter.
- Legal matters: The company reported no material legal proceedings pending and no material changes to the risk factors in its prior annual report.
Key facts investors should verify
- Whether the remaining Series A-1 proceeds were received and whether the proposed credit facility and optional equity financing closed, on what terms, and for how much.
- Current liquidity, cash runway and steps to address the disclosed going-concern uncertainty.
- Status and timing of the planned TVGN 489 pivotal trial, other development programs, and related funding and manufacturing needs.
- Resolution and current status of the Polar note default, including any obligations or consequences involving the Sponsor.
- Potential dilution from preferred stock, warrants, earnout shares and equity awards, and the share count after quarter-end.
- Progress in remediating material weaknesses in internal controls, and the effects of the unusually large merger-related stock compensation and fair-value adjustments.